Quick Answer
Phio Pharmaceuticals Corp. reported Cash and Equivalents of $21.03 million for fiscal year 2025.
Phio Pharmaceuticals Corp. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $21.03M | +290.8% |
| 2024 | $5.38M | -36.6% |
| 2023 | $8.49M | +137.1% |
| 2017 | $3.58M | -72.3% |
| 2016 | $12.91M | +152.2% |
| 2015 | $5.12M | -39.8% |
| 2014 | $8.50M | -25.4% |
| 2013 | $11.39M | +122.2% |
| 2012 | $5.13M | +919.3% |
| 2011 | $503.0K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $10.71M | +98.6% | -0.6% |
| June 30, 2025 | $10.78M | +129.4% | -18.9% |
| March 31, 2025 | $13.28M | +105.1% | +146.7% |
| December 31, 2024 | $5.38M | -36.6% | -0.1% |
| September 30, 2024 | $5.39M | -35.9% | +14.7% |
| June 30, 2024 | $4.70M | -58.5% | -27.4% |
| March 31, 2024 | $6.47M | — | -23.7% |
| December 31, 2023 | $8.49M | — | +1.0% |
- Phio Pharmaceuticals Corp. showed an increase of +290.8% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2011–2025 period, Phio Pharmaceuticals Corp.’s cash and equivalents has grown by 4081.1% (from $503.0 thousand to $21.03 million).
- The most recent figure is from Phio Pharmaceuticals Corp.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: